EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Genome‐wide associations with metabolic syndrome among UK Biobank participants reporting use of second‐generation antipsychotics

Nihal El Rouby iD, Aniwaa Owusu-Obeng, Michael Preuss, Simon Lee, Mingjian Shi, Michael Lape, Lisa J Martin, Bahram Namjou-Khales, Leah C Kottyan, Sara L Van Driest, Jonathan D Mosley, Melissa P DelBello

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025

DOI: 10.1002/phar.70041 ↗

At a glance

Journal article in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2025. Written by Nihal El Rouby and 11 co-authors. Institution: Division of Pharmacy Practice and Administrative Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA. Major MEDLINE topics: Metabolic Syndrome, Antipsychotic Agents. 55 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: ACCP Foundation.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objectives

Second‐generation antipsychotic (SGA) medications are frequently prescribed for mental health conditions; however, they are associated with an increased risk of metabolic syndrome (MetS). We aimed to identify genetic associations of SGA‐associated MetS (SGA–MetS) using genome‐wide approaches within the UK Biobank. We also set out to evaluate if genetically predicted obesity is associated with an increased risk of SGA–MetS.

Methods

We defined SGA–MetS based on the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) criteria using cross‐sectional data from 1318 UK Biobank participants who reported being on an SGA medication. An SGA–MetS case was defined as meeting three or more of the five NCEP‐ATP III criteria. We performed a genome‐wide association study (GWAS) and gene‐based analysis to identify significant variants and gene associations. We computed the polygenic risk score (PGS) for body mass index (BMI) using 2,100,302 variants validated for obesity and metabolic traits from imputed single‐nucleotide polymorphism (SNP) data. We tested the association of PGS–BMI with SGA–MetS using logistic regression.

Results

GWAS identified suggestive associations ( p < 1 × 10 −5 ) on chromosome 15. The variant rs12914956 in CHD2 was associated with increased risk of SGA (odds ratio (OR) = 1.73, 95% confidence interval (CI) = 1.4–2.4, p = 3.6 × 10 −7 ). The gene‐based analysis identified significant gene associations with RBFOX1 ( p = 4.85 × 10 −7 ), PTPRD ( p = 7.6 × 10 −7 ), CSMD1 ( p = 2.2 × 10 −6 ), and CHD2 ( p = 1.3 × 10 −6 ). The PGS–BMI ( β = 0.23, p = 6.8 × 10 −5 ), was associated with increased MetS in a model adjusted for age, sex, physical activity, alcohol consumption, antidepressant medications, schizophrenia diagnosis, and principal components of ancestry.

Conclusion

Using a gene‐based analysis, we identified significant gene associations with SGA–MetS that have been previously associated with obesity and metabolic traits. The PGS–BMI was associated with MetS, suggesting that a genetic predisposition to a higher BMI may increase the risk of SGA–MetS. Future research should replicate the findings in a larger dataset with more diverse populations.

Subjects

MeSH terms (MEDLINE)

Metabolic SyndromeAntipsychotic AgentsHumansGenome-Wide Association StudyFemaleMaleUnited KingdomMiddle AgedBiological Specimen BanksCross-Sectional StudiesPolymorphism, Single NucleotideBody Mass IndexObesityAgedAdultUK Biobank

Author keywords

genome wide association studymetabolic syndromepharmacogenomicssecond generation antipsychotics

Substances

Antipsychotic Agents

Authors and institutions

  • Division of Pharmacy Practice and Administrative Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA.
  • St. Elizabeth HealthCare, Edgewood, Kentucky, USA.
  • Department of Psychiatry & Behavioral Neuroscience, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
  • The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Biomedical Informatics, VUMC, Nashville, Tennessee, USA.
  • Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

ORCID profiles: Nihal El Rouby

Funding

  • ACCP Foundation

Cite

APA

Rouby, N. E., Owusu-Obeng, A., Preuss, M., Lee, S., Shi, M., Lape, M., Martin, L. J., Namjou-Khales, B., Kottyan, L. C., Van Driest, S. L., Mosley, J. D., & DelBello, M. P. (2025). Genome‐wide associations with metabolic syndrome among UK Biobank participants reporting use of second‐generation antipsychotics. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70041

Vancouver

Rouby NE, Owusu-Obeng A, Preuss M, Lee S, Shi M, Lape M, et al. Genome‐wide associations with metabolic syndrome among UK Biobank participants reporting use of second‐generation antipsychotics. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025. doi:10.1002/phar.70041

BibTeX
@article{Rouby2025,
  author = {Rouby, Nihal El and Owusu-Obeng, Aniwaa and Preuss, Michael and Lee, Simon and Shi, Mingjian and Lape, Michael and Martin, Lisa J and Namjou-Khales, Bahram and Kottyan, Leah C and Van Driest, Sara L and Mosley, Jonathan D and DelBello, Melissa P},
  title = {Genome‐wide associations with metabolic syndrome among UK Biobank participants reporting use of second‐generation antipsychotics},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2025},
  doi = {10.1002/phar.70041}
}
Start for free →